MX366197B - Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno. - Google Patents

Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno.

Info

Publication number
MX366197B
MX366197B MX2014003854A MX2014003854A MX366197B MX 366197 B MX366197 B MX 366197B MX 2014003854 A MX2014003854 A MX 2014003854A MX 2014003854 A MX2014003854 A MX 2014003854A MX 366197 B MX366197 B MX 366197B
Authority
MX
Mexico
Prior art keywords
monitoring method
nitrogen
therapeutic monitoring
nitrogen cleaning
drugs
Prior art date
Application number
MX2014003854A
Other languages
English (en)
Other versions
MX2014003854A (es
Inventor
Scharschmidt Bruce
Mokhtarani Masoud
Original Assignee
Horizon Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366197(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc
Publication of MX2014003854A publication Critical patent/MX2014003854A/es
Publication of MX366197B publication Critical patent/MX366197B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y10T436/175383—Ammonia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención se refiere a métodos para evaluar la exposición de amoníaco diario con base en una medición única del nivel en sangre de amoníaco en ayunas, así como también métodos que utilizan esta técnica para ajustar la dosificación de un fármaco depurador de nitrógeno, determinar ya sea administrar un fármaco depurador de nitrógeno, y tratar trastornos de retención de nitrógeno.
MX2014003854A 2011-09-30 2012-03-09 Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno. MX366197B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542100P 2011-09-30 2011-09-30
US201161564668P 2011-11-29 2011-11-29
PCT/US2012/028620 WO2013048558A2 (en) 2011-09-30 2012-03-09 Methods of therapeutic monitoring of nitrogen scavenging drugs

Publications (2)

Publication Number Publication Date
MX2014003854A MX2014003854A (es) 2014-10-17
MX366197B true MX366197B (es) 2019-06-25

Family

ID=47892277

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003854A MX366197B (es) 2011-09-30 2012-03-09 Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno.
MX2019006900A MX2019006900A (es) 2011-09-30 2014-03-28 Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019006900A MX2019006900A (es) 2011-09-30 2014-03-28 Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno.

Country Status (25)

Country Link
US (21) US8404215B1 (es)
EP (2) EP2760479B1 (es)
JP (2) JP6073898B2 (es)
KR (2) KR102019000B1 (es)
CN (2) CN104039358A (es)
AU (2) AU2012316750B2 (es)
BR (1) BR112014007357B1 (es)
CA (1) CA2850391A1 (es)
CL (1) CL2014000783A1 (es)
CY (1) CY1119028T1 (es)
DK (1) DK2760479T3 (es)
ES (1) ES2629859T3 (es)
HR (1) HRP20171063T1 (es)
HU (1) HUE035220T2 (es)
IL (2) IL231732A (es)
LT (1) LT2760479T (es)
MX (2) MX366197B (es)
PL (1) PL2760479T3 (es)
PT (1) PT2760479T (es)
RS (1) RS56196B1 (es)
SG (1) SG11201400781TA (es)
SI (1) SI2760479T1 (es)
SM (1) SMT201700321T1 (es)
WO (1) WO2013048558A2 (es)
ZA (1) ZA201401851B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760479B1 (en) 2011-09-30 2017-05-03 Horizon Therapeutics, LLC Nitrogen scavenging drug for use in a method of treating a nitrogen retention disorder
AU2012377389A1 (en) 2012-04-20 2014-10-30 Horizon Therapeutics Llc Methods of therapeutic monitoring of phenylacetic acid prodrugs
DK2922576T3 (en) * 2012-11-21 2018-01-15 Horizon Therapeutics Llc PROCEDURES FOR THE ADMINISTRATION AND EVALUATION OF NITROGEN RINSE MEDICINES FOR TREATING HEPATIC ENCYPHALOPATHY
WO2015048818A1 (en) * 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
HUE045106T2 (hu) * 2013-10-14 2019-12-30 Immedica Pharma Ab Eljárások a karbamidciklus rendellenességeinek kezelésére
MX383005B (es) 2013-11-14 2025-03-13 Ultragenyx Pharmaceutical Inc Composiciones solidas de trigliceridos y usos de estas.
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
CN106573070A (zh) 2014-08-13 2017-04-19 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
JP7088473B2 (ja) 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
WO2017147193A1 (en) * 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JP6752748B2 (ja) 2017-03-30 2020-09-09 住友重機械工業株式会社 減速装置
EP3649474A1 (en) * 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
MX2020002057A (es) * 2017-08-22 2020-07-13 Regeneron Pharma Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
CN115103690B (zh) 2019-12-04 2026-01-23 阿什瓦塔治疗股份有限公司 用于将药物递送至眼的树枝状大分子组合物和方法
US20230248657A1 (en) * 2020-07-07 2023-08-10 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004595A (en) 1911-05-25 1911-10-03 Sargents Sons Corp C G Carrier for washing-bowls.
US1018300A (en) 1911-06-12 1912-02-20 John Davidson Condensing steam-engine.
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE69612755T2 (de) 1995-02-07 2001-08-23 Brusilow Enterprises, Llc Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
DE19805854C1 (de) 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
IT1317073B1 (it) 2000-12-12 2003-05-26 Mini Ricerca Scient Tecnolog Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US6825384B1 (en) 2004-01-29 2004-11-30 The Nutrasweet Company Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
SG158073A1 (en) * 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
EP2237684A2 (en) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
HRP20161222T1 (hr) 2008-08-29 2017-02-10 Horizon Therapeutics, Llc Postupci liječenja koristeći lijekove za izbacivanje amonijaka
EP2338050A1 (en) 2008-08-29 2011-06-29 Ucyclyd Pharma, Inc. Dosing and monitoring patients on nitrogen-scavenging drugs
ES2546526T3 (es) 2009-07-24 2015-09-24 Baylor College Of Medicine Métodos de modulación de ácidos de cadena ramificada y usos de los mismos
WO2012008228A1 (ja) 2010-07-16 2012-01-19 第一三共株式会社 アルコール類の酸化方法
US20130224277A1 (en) 2010-08-31 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
EP2760479B1 (en) 2011-09-30 2017-05-03 Horizon Therapeutics, LLC Nitrogen scavenging drug for use in a method of treating a nitrogen retention disorder
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
AU2012377389A1 (en) 2012-04-20 2014-10-30 Horizon Therapeutics Llc Methods of therapeutic monitoring of phenylacetic acid prodrugs
DK2922576T3 (en) 2012-11-21 2018-01-15 Horizon Therapeutics Llc PROCEDURES FOR THE ADMINISTRATION AND EVALUATION OF NITROGEN RINSE MEDICINES FOR TREATING HEPATIC ENCYPHALOPATHY
CN103304402B (zh) 2013-05-24 2015-04-22 苏州诚和医药化学有限公司 一种制备4-苯-1-丁酸的方法
WO2015048818A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
HUE045106T2 (hu) 2013-10-14 2019-12-30 Immedica Pharma Ab Eljárások a karbamidciklus rendellenességeinek kezelésére
IN2013MU03442A (es) 2013-10-30 2015-07-17 Lupin Ltd
ES2748294T3 (es) 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
WO2017147193A1 (en) 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Also Published As

Publication number Publication date
US20130085179A1 (en) 2013-04-04
US20180055807A1 (en) 2018-03-01
IL254134A0 (en) 2017-10-31
US9095559B2 (en) 2015-08-04
KR20180085823A (ko) 2018-07-27
US20180221326A1 (en) 2018-08-09
CA2850391A1 (en) 2013-04-04
US9962359B2 (en) 2018-05-08
US20180015064A1 (en) 2018-01-18
WO2013048558A2 (en) 2013-04-04
LT2760479T (lt) 2017-07-10
MX2019006900A (es) 2019-09-04
US8404215B1 (en) 2013-03-26
US20180263949A1 (en) 2018-09-20
US20160199334A1 (en) 2016-07-14
EP2760479A2 (en) 2014-08-06
EP3263102A1 (en) 2018-01-03
US20130210914A1 (en) 2013-08-15
US9999608B2 (en) 2018-06-19
US20150335605A1 (en) 2015-11-26
EP2760479A4 (en) 2015-08-26
JP2017067791A (ja) 2017-04-06
US10617665B2 (en) 2020-04-14
JP6425746B2 (ja) 2018-11-21
US10183002B2 (en) 2019-01-22
US10183005B2 (en) 2019-01-22
US20160081969A1 (en) 2016-03-24
US20160199332A1 (en) 2016-07-14
US10183003B2 (en) 2019-01-22
CN107271696A (zh) 2017-10-20
US20180021291A1 (en) 2018-01-25
US9962358B2 (en) 2018-05-08
US9254278B2 (en) 2016-02-09
CN104039358A (zh) 2014-09-10
US10045959B1 (en) 2018-08-14
SG11201400781TA (en) 2014-04-28
BR112014007357A2 (pt) 2017-04-04
US20190125713A1 (en) 2019-05-02
IL231732A0 (en) 2014-05-28
US20210000784A1 (en) 2021-01-07
ZA201401851B (en) 2018-05-30
US20180235920A1 (en) 2018-08-23
CY1119028T1 (el) 2018-01-10
US20180221327A1 (en) 2018-08-09
US20160199333A1 (en) 2016-07-14
HRP20171063T1 (hr) 2017-10-06
JP6073898B2 (ja) 2017-02-01
HUE035220T2 (hu) 2018-05-02
ES2629859T3 (es) 2017-08-16
RS56196B1 (sr) 2017-11-30
US10183006B2 (en) 2019-01-22
BR112014007357B1 (pt) 2022-12-06
US20180221325A1 (en) 2018-08-09
US10183004B2 (en) 2019-01-22
KR102019000B1 (ko) 2019-09-05
WO2013048558A3 (en) 2014-04-03
SI2760479T1 (sl) 2017-07-31
US20180021293A1 (en) 2018-01-25
SMT201700321T1 (it) 2017-09-07
JP2014532179A (ja) 2014-12-04
US10045958B1 (en) 2018-08-14
KR20140094517A (ko) 2014-07-30
MX2014003854A (es) 2014-10-17
AU2012316750A1 (en) 2014-03-27
DK2760479T3 (en) 2017-07-17
US20180221324A1 (en) 2018-08-09
US20160202240A1 (en) 2016-07-14
PT2760479T (pt) 2017-07-21
EP2760479B1 (en) 2017-05-03
US20180263948A1 (en) 2018-09-20
PL2760479T3 (pl) 2017-09-29
CL2014000783A1 (es) 2015-01-16
US9326966B2 (en) 2016-05-03
AU2017251691A1 (en) 2017-11-09
IL231732A (en) 2017-09-28
AU2012316750B2 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MX366197B (es) Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno.
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
ES2675779T3 (es) Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
BR112012032282A2 (pt) administração transdérmica de memantina
EA201590586A1 (ru) Терапевтические наночастицы, включающие терапевтический агент, способы их получения и применения
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201391087A1 (ru) Оральные лекарственные формы препарата тазоцитиниба с модифицированным высвобождением
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
EA201370008A1 (ru) Лечение когнитивных нарушений
HUE041944T2 (hu) Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére
EA201500426A1 (ru) Производные пирролотриазинона в качестве ингибиторов pi3k
MX350046B (es) Tratamientos para trastornos gastrointestinales.
EP2701700A4 (en) PHARMACOTHERAPY FOR PREVENTING ADVERSE EFFECTS INDUCED BY CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING METHODS AND KITS THEREOF
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
HK1210699A1 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
MX365302B (es) Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: HORIZON THERAPEUTICS, LLC

HC Change of company name or juridical status

Owner name: HORIZON THERAPEUTICS, LLC

FG Grant or registration